Digital care programme tested in adults with psoriatic arthritis

Trial details

Who runs it

Sociedade Portuguesa de Reumatologia

Trial code

NCT07772544

Record updated

16 September 2026

Original description

This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world clinical practice.Read full original descriptionShow less

iPROLEPSIS-PPIDC: Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world clinical practice.

The study will enrol 72 adults with PsA (18 participants per country) across Portugal, the Netherlands, Greece, and the United Kingdom. Participants will be followed for 12 months, including a 1-month baseline monitoring period without intervention, followed by an 11-month intervention period during which participants will use the iPROLEPSIS digital health ecosystem. The iPROLEPSIS ecosystem integrates multiple digital health tools designed to support lifestyle management, self-monitoring, and patient engagement in PsA care. Participants will use the miPROLEPSIS app for active and passive data collection and personalised lifestyle recommendations related to diet and physical activity; biAURA for sleep and stress management using binaural beats; iPROLEPSIS Games to promote physical and emotional well-beingthrough serious games; and the miPROLEPSIS Joint Landmarker app for video-based functional assessments. The ecosystem will also integrate data from a Garmin vívoactive 5 smartwatch and wireless earbuds. Healthcare professionals involved in participant follow-up will access a dedicated clinical dashboard to support monitoring and clinical management. The primary objective of this feasibility study is to evaluate the usability of the iPROLEPSIS digital health ecosystem among patients with PsA and healthcare professionals using the System Usability Scale (SUS) and the eHealth UsaBility Benchmarking Instrument (HUBBI). Secondary objectives include assessing participant retention, acceptability of study participation, engagement with the digital health tools, adherence to study procedures, and identifying barriers and facilitators influencing the implementation of the digital health programme in routine clinical practice.The study will also generate preliminary evidence regarding potential changes in clinical and patient-reported outcomes associated with the use of the iPROLEPSIS ecosystem and include a preliminary budget impact analysis to inform the design of a future larger-scale clinical trial.

Inclusion: Willing and able to provide informed consent; Female or male, aged 18 years or older at the time of enrolment; Diagnosed with psoriatic arthritis; Had a rheumatology appointment in the past 12 months; Owns a smartphone (Android) compatible with the study apps; Willing to use the study smartwatch (Garmin Vivoactive 5) for the 12-month follow-up period; Proficient in the local language; Willing and able to provide informed consent; Involved in the clinical follow-up of PsA patients enrolled in the study.

Exclusion: Illiteracy or inability to comply with the study protocol (e.g., due to hearing or visual impairments or significant cognitive impairment); Lack of access to the necessary technology to participate in the study (e.g., smartphone or stable internet connection).

ClinicalTrials.gov NCT07772544